Sonova Stock - weekly review and sector comparison
19.06.2026 - 13:49:19 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 13:48 CET. Details in the imprint.
Sonova (CH0012549785) is closing out the week without any new ad-hoc releases or major headlines from top financial wires. With no fresh corporate news, the focus turns to how the Swiss hearing-care stock has performed recently and how it stacks up against sector peers.
All news and background on Sonova stock
Key figures, company reports and further Sonova coverage are bundled on our topic page and on the company's investor-relations site.
How Sonova shares ended the week
Sonova shares are traded on SIX Swiss Exchange under the ticker SOON in Swiss francs. According to the Swiss exchange quote overview, the stock recently traded around CHF 280, corresponding to a market capitalization of roughly CHF 17 billion.
The shares remain below their 52-week high but comfortably above last year's lows, reflecting a medtech name that has stabilized after pandemic and supply-chain disruptions. Compared with early-year levels, the stock has moved broadly in line with the wider Swiss health care segment.
Position versus hearing-care peers
In the global hearing-aids market, Sonova competes primarily with Demant, GN Store Nord and WS Audiology, as well as cochlear-implant specialist Cochlear. Analysts typically group these names as a defensive, cash-generative medtech niche.
Recent sector commentary from European brokers highlights steady structural demand, supported by aging populations and better diagnosis rates, but also notes pricing pressure in some regions and growing competition from over-the-counter hearing devices in the US.
Analyst sentiment and expectations
Consensus data compiled by major financial portals shows that most covering analysts rate Sonova between Hold and Buy, with only a minority on Sell. Price targets tend to cluster moderately above the current share price, indicating a cautiously positive stance.
On earnings, the market expects mid single-digit to low double-digit percentage growth in sales over the next financial year, driven by volume growth in hearing instruments and ongoing recovery in cochlear implants.
The product behind the stock
Sonova generates most of its revenue from hearing instruments, including the Phonak-branded rechargeable hearing aids and wireless accessories. The group also sells cochlear implants and operates retail audiological care networks, especially in Europe and North America.
Where the stock trades today
Sonova shares (CH0012549785) trade on SIX Swiss Exchange at CHF 280.00 as of 06/19/2026, 13:30 CET.
Key facts on Sonova stock
- Company: Sonova Holding AG
- ISIN: CH0012549785
- WKN: 125497
- Ticker: SOON
- Venue: SIX Swiss Exchange
- Price (as of 06/19/2026, 13:30 CET): 280.00 CHF
- Market cap: 17,000,000,000 CHF (as of 06/19/2026)
- Sector / Industry: Health Care - Hearing Aids & Devices
- Index membership: Swiss Market Index (SMI)
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
